Activation of TP53 target genes in the primary response of triple-negative breast cancer cells to doxorubicin treatment
Abstract Among the DNA-damaging agents commonly used in clinical settings doxorubicin has emerged as one of the most effective treatments for Triple-negative breast cancer (TNBC). Our limited understanding about the molecular mechanisms underlying the short- and long-term responses of TNBC cells to...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Nature Portfolio
2025-12-01
|
| Serie: | Scientific Reports |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1038/s41598-025-31087-x |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|